Abstract
The amino acid glutamine has numerous important roles including particularly antioxidant defence, immune function, the inflammatory response, acid–base balance and N economy. The present systematic review of randomised controlled trials of nutrition support with glutamine up to August 2008 has found that parenteral glutamine in critical illness is associated with a non-significant reduction in mortality (risk ratio 0·71 (95% CI 0·49, 1·03)) and may reduce infections. However, poor study quality and the possibility of publication bias mean that these results should be interpreted with caution. There is no evidence to suggest that glutamine is harmful in terms of organ failure and parenteral glutamine may reduce the development of organ failure.
Publisher
Cambridge University Press (CUP)
Subject
Nutrition and Dietetics,Medicine (miscellaneous)
Reference50 articles.
1. 10. Wu T , Li Y , Liu G (2006) Investigation of authenticity of ‘claimed’ randomized controlled trials (RCTs) and quality assessment of RCT reports published in China. Proceedings of the XIV Cochrane Colloquium, Dublin 23–26 October, p. 52. Oxford: The Cochrane Collaboration.
2. Parenteral l-alanyl-l-glutamine improves 6-month outcome in critically ill patients*
3. Glutamine as a modulator of the immune system of critical care patients: Effect on Toll-like receptor expression. A preliminary study
4. Glutamine administration reduces Gram-negative bacteremia in severely burned patients: A prospective, randomized, double-blind trial versus isonitrogenous control
5. 6. Critical Care Nutrition (2008) Clinical practice guideline for nutrition support in the mechanically ventilated, critically ill adult patient. http://www.criticalcarenutrition.com/index.php?option=com_content&task=view&id=17&Itemid=40 (accessed December 2008).
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献